SPRY — ARS Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1671858 ·
Last close
$3.65
Market Cap
$366.93M
52W High
$13.15
52W Low
$2.44
ADV30
2,116,931
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 37,710,000 27,612,000 -34,171,000 -35,587,000 251,484,000 25,621,000 263,439,000
Jun 2026 33,658,000 20,812,000 -61,465,000 -62,339,000 249,495,000 8,163,000 236,983,000
Mar 2026 22,681,000 16,395,000 -60,145,000 -60,618,000 287,571,000 24,321,000 226,263,000
Dec 2025 28,087,000 21,933,000 -41,465,000 -41,324,000 327,652,000 41,317,000 213,394,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-196,405,000
Investing CF
$48,496,000
Financing CF
$104,532,000
CapEx
$-339,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.22
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-417,560,000
Inventory
$11,689,000
Receivables
$46,839,000
ST Investments
$135,682,000
EBIT TTM
$-202,025,000
Pretax Income TTM
$-215,512,000
Interest Exp TTM
$4,920,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$122,136,000
EBITDA
$-195,600,992
Free Cash Flow
$-113,209,128
Enterprise Value
$339,135,232
Total Cash
$138,354,000
Total Debt
$197,015,008
Shares Out
100,528,400
Trailing EPS
$-2.01
Book Value
$-0.12
ROE
-294.6%
ROA
-39.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 84,278,000 -179,448,000 -171,298,000 327,652,000 213,394,000 114,258,000 -170,866,000
Dec 2024 89,149,000 -3,083,000 7,998,000 351,153,000 94,355,000 256,798,000 13,548,000
Dec 2023 30,000 -67,520,000 -54,365,000 233,188,000 2,428,000 230,760,000 -59,266,000
Dec 2022 1,316,000 -35,516,000 -34,682,000 281,435,000 8,549,000 272,886,000 -40,078,000

TTM Snapshot

Revenues TTM
$116,927,000
NetIncome TTM
$-215,432,000
OpCashFlow TTM
—
Assets (Latest)
$249,495,000
Forward EPS
$-0.90

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $3.69 · call volume: 32 · put volume: 2
Expected Move to 2026-12-18: ±$1.43 (38.62%) — implied range $2.27 – $5.12 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CYDY CytoDyn Inc. $366.64M $0.25 —
PEPG PepGen Inc. $365.73M $3.88 —
PBYI PUMA BIOTECHNOLOGY, INC. $369.13M $7.14 —
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —
CRMD CorMedix Inc. $371.44M $4.67 —

News headlines (Yahoo Finance, 1h cache)

ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
2026-11-06 11:16 · Yahoo
ARS Pharmaceuticals Q3 Earnings Call Highlights
2026-11-06 04:14 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 21:45 · Yahoo
ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2026-10-29 13:00 · Yahoo
ARS Pharma to Report Third Quarter 2026 Financial Results
2026-10-28 20:01 · Yahoo
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-01 20:01 · Yahoo
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
2026-08-20 13:55 · Yahoo
ARS Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 03:04 · Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 21:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.